Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852479 | 0.88 | GPR139 (0.51) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL20581332 | 0.85 | CYP2C9 (0.46) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL4980126 | 0.84 | GPR139 (0.43) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL30277283 | 0.82 | CYP2C9 (0.48) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL19962270 | 0.82 | CYP2C9 (0.48) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL30050122 | 0.82 | GPR139 (0.52) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL27160041 | 0.82 | GPR139 (0.52) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL27160044 | 0.82 | GPR139 (0.52) | CYP2C9NR1I2GPR139MAPK1CYP2C8 | |
| SCHEMBL14313728 | 0.81 | GPR139 (0.51) | CYP2C9NR1I2GPR139MAPK1P2RX3 | |
| SCHEMBL2719084 | 0.79 | L3MBTL1 (0.55) | CYP2C9MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-2860178-B1 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-30 | — | — | US | disclosed |
| US-10472354-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20190185466-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-06-20 | — | — | US | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| EP-2215048-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2860178-A2 | P2X3 receptor antagonists for treatment of pain | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2358371-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8598209-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8461185-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CYP2C9 4126/4885NR1I2 598/4885GPR139 147/4885 |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | CYP2C9 4126/4885NR1I2 598/4885GPR139 147/4885 |
| US-20190185466-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-10472354-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CYP2C9 3902/4885NR1I2 579/4885GPR139 122/4885 |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2C9 1392/4885NR1I2 1353/4885GPR139 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.